Fig. 1: Glucose labelling of brain tumours and cortex.
From: Rewiring of cortical glucose metabolism fuels human brain cancer growth
a, Schematic of [U13C]glucose infusions and analyses of patients with glioma and patient-derived intracranial GBM mouse models. The diagram was created using BioRender. b, Example of magnetic-resonance-imaging-defined tissue acquisition. c, Arterial m+6 glucose enrichment in patients undergoing [U13C]glucose infusions at the indicated times after the start of infusion. Plasma from patient 8 could not be analysed at time 0. The triangles indicate the tissue resection and flash-freezing timepoint. d, Arterial m+6 glucose enrichment in mice undergoing [U13C]glucose infusions. Data are mean ± s.d. at each timepoint. e,f, Normalized (to labelled plasma glucose on a per-patient (e) or per-mouse (f) basis) enrichment of glycolytic intermediates in intracranial tissues from eight patients with glioma (e) or mouse models (f) infused with [U13C]glucose. Data are mean ± s.d. Comparisons between groups were performed using linear mixed-effects models with a random intercept for individual. For each metabolite, multiple pairwise comparisons across tissue types were adjusted using Holm’s method. Statistical tests were two-sided. g, H&E staining of GBM38 patient-derived xenograft (PDX) grown orthotopically (left) and MALDI image showing 13C enrichment of lactate (right) with the tissue maximum set at 100%. Imaging with a separate, independent instrument was performed once and produced similar results. Scale bar, 3 mm. FBP, fructose 1,6-bisphosphate; GAP, glyceraldehyde 3-phosphate; DHAP, dihydroxyacetone phosphate; 3PG/2PG, 3-phosphoglycerate/2-phosphoglycerate; PEP, phosphoenolpyruvate.
